Renin–Angiotensin–Aldosterone System Inhibitors, commonly used to treat hypertension, have a role in ACE2 homeostasis and it is possible that a modification in quantity and site of ACE2 expression could modify susceptibility and disease outcome [29]. This evidence concerns the gene ACE2 and hypertensive disorder.